MetrioPharm Investor Relations News QII 2022

16th Annual General Meeting of MetrioPharm AG

On June 23, 2022, the 16th Annual General Meeting of MetrioPharm AG was held in the plenary room of KV Business School Zurich. With the Annual Report 2021, the Management and the Board of MetrioPharm AG provided an overview of the company's initiatives over the past year. MetrioPharm AG was able to strengthen its equity by CHF 27.5 million in May last year. In November 2021, MetrioPharm signed a grant agreement from the European Commission for € 7.9 million. In addition, management and the Board also provided an outlook on current strategic developments of the company.

In addition, the status quo of the ongoing Phase II clinical trial in the indication COVID-19 was reported. Recently, the last patient was enrolled in this study. In addition to confirming the safety profile of MP1032, the objectives of the study are to determine the primary endpoint, which is the percentage of patients whose disease symptoms were alleviated on day 14 by treatment with MP1032. Initial topline data are expected in H2 2022.

After approval of the Annual Report and Accounts 2021 and discharge of the Board of directors Mr. Markus Wenner and Dr. Werner Wolf were confirmed in office for another 3 years.

The Annual General Meeting of MetrioPharm AG resolved to amend Article 11 of the Articles of Incorporation in order to add another person to the Board. This extension is made in order to be able to add another member to the Board who can demonstrate extensive experience and a corresponding track record in the pharmaceutical industry.

Of the total share capital of CHF 34,465,004.40, divided into 172,325,022 registered shares with a par value of CHF 0.20, 134,071,857 shares were represented. This corresponds to 75.71% of the shares issued.

MetrioPharm at Bio-Europe Spring in Basel, Switzerland

Due to the ongoing Corona pandemic, this year's international industry meeting took place exclusively virtually in Basel from March 28 to 30. Decision-makers from the biotechnology, pharmaceutical and financial sectors established contacts with companies and cultivated existing partnerships via the digital partnering platform. MetrioPharm's CEO Thomas Christély and CSO Dr. Wolfgang Brysch used Bio-Europe Spring to meet potential pharma partners for planned fixed-dose combination therapies. The goal is to combine drugs of existing standard therapies at lower doses with MP1032 in a single pill to produce novel drugs with improved efficacy and fewer side effects. Potential pharma partners were also informed about the current status of patient recruitment for MetrioPharm's ongoing Phase II study in COVID-19.

MetrioPharm attends the BIO International Convention in San Diego, USA

MetrioPharm's CEO Thomas Christély and CSO Dr. Wolfgang Brysch attended this year's in-person event of the BIO International Convention in San Diego from June 13-16. The world's largest biotechnology conference, with an extensive attendee list of reputable pharmaceutical companies and investors, offered the opportunity on an even larger scale than at BioEurope Spring to approach potential pharma partners for planned fixed-dose combination therapies as well as investors for the next capital increase. Both, pharmaceutical companies and potential investors were informed about the successful completion of patient enrollment in the ongoing Phase II study in COVID-19, as well as the results available in H2 2022.

MetrioPharm AG Company Calendar in QIII 2022

15-16th September 2022: China Bio Partnering Forum, Beijing, China (Digital)
24-26th October 2022: Bio-Europe, Leipzig, Deutschland

London-Paris in 24 hours – by bike

MetrioPharm founder and CSO Dr. Wolfgang Brysch pedaled for a good cause in early June. He participated in the "Duchenne Dash" of the charity Duchenne UK (DUK), a bike ride from London to Paris in 24 hours. "I was first exposed to Duchenne muscular dystrophy 5 years ago through our work with our compound MP1032. At that time, a researcher and physician in the field had pointed out to us that our drug could also help with this disease. Duchenne muscular dystrophy (also known as muscle loss) is a devastating genetic disease and occurs in about 1 in 5,000 newborn boys," Brysch said. Our picture shows Dr. Wolfgang Brysch (left) and Alasdair Robertson from Duchenne UK. 

MetrioPharm AG informs

MetrioPharm uses various channels to inform its shareholders:

  • In addition to the quarterly newsletter, we also keep you informed about current events in the company with press releases. The press releases can also be found on our website here. If you have not yet been added to our distribution list for press releases, please send us an e-mail at invest@metriopharm.com and we will add you to the distribution list as soon as possible.
  • In November 2021, MetrioPharm signed a grant agreement from the European Commission for € 7.9 million. The project "iMPact" was among the 6 initiatives selected by the Commission to work on compounds for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19, as well as preclinical studies on the effect of MP1032 on mutant variants of SARS-CoV-2. More information on the iMPact project can be found here.
  • You can also network with MetrioPharm via LinkedIn. We use our LinkedIn profile to inform shareholders, experts and business partners about the latest company developments. Please feel free to include us in your LinkedIn community by invitation.


Your contact:

MetrioPharm AG Eva Brysch Investor Relations Managerin          

Lia Petridou
Corporate Communications & Press Relations

T +49 (0) 30 33 84 395 53
F +49 (0) 30 33 84 395 99
E press@metriopharm.com
W www.metriopharm.com



MetrioPharm AG Download PDF